Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Fatemeh Naddafi, Farshad H. Shirazi, Yeganeh Talebkhan, Maryam Tabarzad, Farzaneh Barkhordari, Zahra Aliabadi Farahani, Elham Bayat, Reza Moazzami, Fereidoun Mahboudi & Fatemeh Davami. (2018) A comparative study of the bispecific monoclonal antibody, blinatumomab expression in CHO cells and E. coli. Preparative Biochemistry & Biotechnology 48:10, pages 961-967.
Read now
Read now
Articles from other publishers (5)
Pauline Mocquot, Yasmine Mossazadeh, Léopoldine Lapierre, Fanny Pineau & Fabien Despas. (2022) The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. Journal of Clinical Pharmacy and Therapeutics 47:9, pages 1337-1351.
Crossref
Crossref
Yun-Hsiang Chen, Yun Wang, Cheng-Hao Liao & Shu-Ching Hsu. (2021) The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy. Scientific Reports 11:1.
Crossref
Crossref
Gordana Wozniak-Knopp. 2021. Introduction to Antibody Engineering. Introduction to Antibody Engineering
161
187
.
Henry T. Marshall & Mustafa B. A. Djamgoz. (2018) Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology 8.
Crossref
Crossref
Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Giovanni Martinelli & Pellegrino Musto. (2016) P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology 7.
Crossref
Crossref